Clareo Health | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1
Has Life expectancy \>= 12 weeks
Adequate organ function
Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable
Histologically confirmed locally advanced or metastatic NSCLC
Absence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)
PD- L1 positive
No prior systemic therapy for locally advanced or metastatic NSCLC
Histologically confirmed recurrent, or metastatic HNSCC
PD-L1 positive
No prior systemic therapy for recurrent or metastatic HNSCC
Histologically confirmed locally advanced or metastatic or unresectable locally advanced cutaneous BRAF WT melanoma or melanomas of unknown primary that are non-mucosal and non -uveal that has progressed on or after treatment that included anti PD1 or anti PD-L1 therapy
Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable, standard therapy is considered inappropriate, or an investigational agent is a recognized standard of care
You may not be if
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
Has leptomeningeal disease or carcinomatous meningitis
Has uncontrolled hypertension
Has left ventricular ejection fraction \< institutional lower limit of normal or \< 50%
Has clinically significant history of liver disease including viral or other hepatitis, current alcohol abuse, or cirrhosis
Has an active or history of autoimmune disease or immune deficiency including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or multiple sclerosis. Participants with a history of autoimmune- related hypothyroidism on thyroid replacement hormone or with controlled Type I diabetes mellitus on a stable dose of an insulin regimen are eligible for this study
